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0022-0736/© 2018 Elsevier Inc. All rights reserved.a b s t r a c ta r t i c l e i n f oKeywords: Objectives: The sensitivity and speciﬁcity of the conventional 12-lead ECG to identify carriers of hypertrophic car-
diomyopathy (HCM) – causing mutations without left ventricular hypertrophy (LVH) has been limited. We
assessed the ability of novel electrocardiographic parameters to improve the detection of HCMmutation carriers.
Methods: We studied 140 carriers (G+) of the TPM1-Asp175Asn orMYBPC3-Gln1061X pathogenic variants for
HCM: The G+/LVH+ group (n = 98) consisted of mutation carriers with LVH and the G+/LVH− group (n =
42)without LVH. The control group consisted of 30 subjects. The standard 12-lead ECGwas comprehensively an-
alyzed and two novel ECG variables were introduced: RV1bRV2NRV3 and septal remodeling. A subset of 65 indi-
viduals underwent cardiac magnetic resonance imaging and 2D strain echocardiography.
Results: Conventional major ECG criteria were sensitive (90%) and speciﬁc (97%) in identifying G+/LVH+ sub-
jects. RV1bRV2NRV3 and septal remodelingweremore prevalent in the G+/LVH− subjects compared to the con-
trol group (33% vs 3%, p=0.005 and 45% vs 3%, p b 0.001, respectively). The combination of RV1bRV2NRV3 andQ
waves and repolarization abnormalities (QR) differentiated between the G+/LVH− subjects and the control
groupwith a sensitivity of 52% and speciﬁcity of 97%. The combination of septal remodeling andQRdifferentiated
between G+/LVH− subjects and the control group with a sensitivity of 64% and speciﬁcity of 97%.
Conclusions: The novel ECG-parameters RV1bRV2NRV3 and septal remodeling were effective in identifying G+/
LVH− subjects and could be useful in the diagnostics of new suspected HCM patients and in the screening and
follow-up of HCM families.
© 2018 Elsevier Inc. All rights reserved.Hypertrophic cardiomyopathy
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ElectrocardiographyIntroduction
Hypertrophic cardiomyopathy (HCM) is the most common
inherited cardiac disease and one of the leading causes of sudden car-
diac death in young people and competitive athletes [1]. To date, over
1500 pathological gene variants in eight genes encoding sarcomeric
proteins have been found [2]. In probands with clinical HCM, however,
a pathogenic variant is identiﬁed in approximately 30–60% of cases
[2,3]. The diagnostic accuracy of identifying individuals at risk forpital, Heart and Lung Center,
-00029 HUS, Finland.developing HCM in families of probands with no identiﬁed variant
needs improvement. Disease development in carriers of pathogenic var-
iants without LVH (G+/LVH−) should also be monitored regularly [3].
The standard 12-lead electrocardiogram (ECG) is an inexpensive and
universally available method used widely in the diagnostics of HCM.
Common ECG ﬁndings in HCM include LVH, abnormal Q waves and re-
polarization abnormalities such as T-wave inversions, ST-segment de-
pression, and prolonged QT [4–8]. However, the sensitivity and
speciﬁcity of the ECG to identify G+/LVH− subjects have been limited
and the prior published data are scarce [4,5,8–10]. In this study our ob-
jective was to investigate previously unreported ECG abnormalities of
R-wave amplitude distribution and QRS conﬁguration in leads V1-V3
to identify carriers of a pathogenic HCM variant with or without
Table 1
Baseline variables of the study groups.
Control G+/LVH− G+/LVH+ p-Value
(n= 30) (n= 42) (n= 98)
Baseline
Female 70% (21) 62% (26) 40% (39)⁎,† 0.004
Age 42 ± 16 33 ± 15 48 ± 14† b0.001
Pathogenic variant
MYBPC3-Gln1061X 88% (37) 62% (61)
TPM-Asp175Asn 12% (5) 38% (37)
NYHA 0.003
I 98% (41) 78% (76)
II 2% (1) 21% (21)
III 1% (1)




Betablocker 7% (3) 23% (23)
ACEi/ARB 2% (1) 22% (22)
Echocardiography
LVEF (%) 62 ± 6 63 ± 6 63 ± 10 0.741
MWT (mm) 10.2 ± 1.1 9.9 ± 1.4 18.7 ± 4.5⁎,† b0.001
SWT (mm) 9.2 ± 1.4 9.6 ± 1.5 16.8 ± 4.0⁎,† b0.001
PWT (mm) 9.1 ± 1.5 8.5 ± 1.2 10.4 ± 1.9⁎,† b0.001
SWT/PWT 1.0 ± 0.1 1.1 ± 0.2 1.6 ± 0.4⁎,† b0.001
LVEDD (mm) 48 ± 5 46 ± 4 46 ± 6 0.152
LAD (mm) 33 ± 4 33 ± 5 41 ± 7⁎,† b0.001
Presented as mean ± SD or percentage and number of subjects in parentheses. ACEi =
angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, ICD =
implantable cardioverter deﬁbrillator, IVCD = intraventricular conduction delay, LAD =
left atrial dimension, LVEDD = left ventricular end-diastolic dimension, LVEF = left
ventricular ejection fraction, MWT = maximal wall thickness, SWT = septal wall
thickness, PWT = posterior wall thickness, RBBB = right bundle branch block, SWT/
PWT= septal to posterior wall thickness ratio.
⁎ p b 0.05 for difference between indicated group and control group.
† p b 0.05 for difference between G+/LVH+ and G+/LVH− groups.
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ﬁndings of mutation carriers with comprehensive imaging data in a
subset of 65 subjects.
Material and methods
Patients
The patients were recruited from families with HCM evaluated at
Kuopio and Helsinki University Hospitals and the Central Hospital of
Central Finland. The study population consisted of 140 subjects carrying
either one of two Finnish founder mutations causing HCM: The
Gln1061X mutation in MYBPC3 or the Asp175Asn mutation in TPM1.
Mutation carriers with documented maximum LV wall thickness
(MWT) ≥13 mm on echocardiography comprised the G+/LVH+
group (n= 98). Mutation carriers without the HCM phenotype (MWT
b 13mm)were classiﬁed as the G+/LVH− group (n=42). The control
group (n = 30) consisted of relatives of individuals with either one of
the two variants, with a structurally normal heart by echocardiography
and who were not carriers of the two studied variants. The Ethics
Committees at the Kuopio and Helsinki University Hospitals approved
the study protocol. The study conforms to the principles outlined in
the Declaration of Helsinki.
Laboratory methods
Venous blood samples were collected and the plasma concentra-
tions of theN-terminal portion of brain natriuretic peptide (NT-proBNP)
were determined with immunoassays utilizing antisera directed to NT-
proBNP. The sensitivity of the assay was 40 pmol/L. The genetic studies
were performed in the Genome Center of Eastern Finland, as previously
described [11].
ECG analysis
All standard 12-lead ECGs, recorded at 50 mm/s speed and
10 mm/mV gain, were analyzed manually by one investigator (KN)
blinded to the clinical data. The amplitudes of the R and S waves were
measured from all the 12 standard ECG leads. The ST segment was con-
sidered elevated or depressed if it was 0.5 mm or more above or below
the baseline, respectively, determined by drawing a line between subse-
quent PR intervals. The T wave was considered negative if it was 1 mm
or more below the baseline. We did not include patients with left bun-
dle branch block or pacemaker ECG.
In addition to the amplitudes of the R and S waves in all the 12 ECG
leads, the following previously described ECG parameters were re-
corded: 1) pathological Q waves: any Q wave ≥40 ms in duration, or
≥3 mm deep, or Q/R-ratio ≥ 0.25, in ≥2 contiguous leads except lead
aVR [12], 2) absence of normal Q wave in V5–V6 [13], 3) highest R
wave in the precordial leads outside of leads V4–V6 [14], 4) LVH accord-
ing to the Sokolow-Lyon criteria (SV1 +maximal R wave amplitude of
V5 or V6 ≥35 mm), 5) LVH according to the Cornell voltage-duration
product deﬁned as: QRS-duration (ms) × (RaVL [mm] + SV3 [mm]).
For women+8mmwas added to the voltage. The product was positive
for LVHwith a cutoff of ≥2440 [15], 6) QRS duration N100ms, 7) RI+SIII
N25 mm [16], 8) RI+SIII-RIII-SI N17 mm [17], 9) S N R in V4 [18], 10)
Romhilt-Estes point score ≥4 suggesting LVH [19], 11) P-terminal force
(PTF; negative portion of the P-wave in lead V1 ≥ 0.04 mm·s), 12) ST-
segment depression ≥0.5mm in ≥2 contiguous leads, 13) T-wave inver-
sion ≥1 mm in ≥2 contiguous leads, except for leads aVR and V1, 14)
frontal plane left, right or superior axis deviation, 15) fragmented QRS
(as deﬁned by Das and Zipes) [20], 16) poor R-wave progression
(PRWP) [21], or 17) reverse R-wave progression in leads V1–V3 [21],
18) rhythm other than sinus, 19) prolonged PR interval, 20) prolonged
QTc interval ≥440 ms (Bazett formula).The electrocardiographic parameters proposed by McKenna et al.
were considered as major criteria for HCM detection, including
pathological Q waves, LVH by Romhilt-Estes score ≥4, and T-wave
inversion (N3 mm) in at least two leads [22]. Composite ECG
criteria were analyzed to aid in clinical identiﬁcation of G+/LVH+
and LVH− subjects (Table 1): Q waves and repolarization abnormal-
ities (QR; repolarization abnormalities = T-wave inversion and/or
ST-segment depression and/or prolonged QTc) and hypertrophy by
Cornell voltage-duration product and/or Sokolow-Lyon criteria
and/or Romhilt-Estes score ≥4.
In addition, we studied two novel ECG parameters. First,
RV1bRV2NRV3, deﬁned as the R wave peak being higher in V2
compared to V1 and V3 (Fig. 1), which we decided to include based
on experience from clinical practice and from pathophysiological
processes involved in HCM. Second, a composite ECG criterion named
septal remodeling was analyzed, which we have previously used in a
study on dilated cardiomyopathy [23]. Septal remodeling was positive
with at least one of the following ﬁndings in the leads V1–V3: (1) path-
ological Q waves in ≥2 contiguous leads, (2) QRS fragmentation in ≥2
leads, (3) PRWP accompanied by QRS fragmentation, or (4) disorderly
distributed R-wave amplitudes, either RV2NRV3 or RV1NRV2. The
possibility of lead switchwas searched for by analyzing themorphology
of the P and S waves in the precordial leads; no suspicious cases were
observed.Echocardiography
All subjects underwent conventional echocardiographic assessment
with emphasis on changes due to HCM. Measurements were made
according to ACC/AHA/ASE guidelines. MWT was measured from 2D
images with optimal beam alignment to the interrogated wall.
Fig. 1. A) The ECG of a 23 y old male with a pathogenicMYBPC3 variant without echocardiographic left ventricular hypertrophy. The R wave in lead V2 is higher than in lead V1 and V3
(RV1bRV2NRV3 sign). B) The ECG of an 18 y old female with a pathogenicMYBPC3 variant without echocardiographic left ventricular hypertrophy. The Rwave in lead V2 is higher than in
lead V1 and V3 (RV1bRV2NRV3 sign). In addition, the R-wave in lead V1 is higher than the R-wave in lead V3. C) An 18-year old male with a pathogenicMYBPC3 variant and increased
septal thickness of 18 mm. The ECG shows the RV1bRV2NRV3 pattern. The R-waves are relatively low in the leads V5 and V6 with a pathological Q/R ratio in lead V6. In addition, there
are Q waves and fragmented QRS complexes in II, III, and aVF, and inverted T-waves in aVL and V2. The Cornell left ventricular hypertrophy criteria are fulﬁlled.
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Comprehensive cardiac magnetic resonance imaging (CMRI) and 2D
strain echocardiography (2DSE) data was available for subset of 65 sub-
jects from the Finnish MYBPC3 imaging study [24], of whom 20 were
control subjects and 45 MYBC3-Gln1061X variant carriers without (G
+/LVH− n= 18) or with LVH (G+/LVH+ n = 27). The methodology
of echocardiography and CMRI for the substudy has been previously
published and is summarized in the Methods section of theSupplementary material [24]. The G+/LVH+ patients were further di-
vided into two groups according to HCM phenotype: mild (n = 12)
and moderate (n = 15) HCM. Patients with moderate HCM were de-
ﬁned as having at least one of the following variables ≥75th percentile
of the HCM group: CMRI left ventricular maximal wall thickness (75th
percentile limit ≥25 mm), echocardiographic global longitudinal strain
(≥−13%), or CMRI measured degree of late gadolinium enhancement
(LGE ≥ 22% of the LV mass). Mild HCM was deﬁned as not fulﬁlling
any of these criteria.
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Categorical variables are expressed as absolute numbers and per-
centages, and continuous variables as means and standard deviations
or medians followed by inter-quartile ranges. Differences between
groups were analyzed using the chi-square test or Fisher's exact test
for categorical variables and the Mann-Whitney or Kruskal-Wallis test
for continuous variables. Binary logistic regression analysis with sex
and age adjustment was used to conﬁrm the validity of the novel ECG
parameters RV1bRV2NRV3 and septal remodeling. The correlation of
the extent of ECG pathology as absolute number of ﬁndings to imaging
and laboratory parameters in the imaging substudy was analyzed with
Spearman rank correlation. A two-tailed p-value of b0.05 was consid-
ered statistically signiﬁcant for all tests. All calculationswere performed
with the SPSS software (IBM SPSS Statistics for Windows, Version 21.0.
Armonk, NY, IBM Corp.).
Results
Baseline
The baseline characteristics and conventional echocardiography
ﬁndings of the three study groups are presented in Table 1 and
Fig. 2A. There were more male subjects in the G+/LVH+ groupFig. 2.Distribution of ECG pathology in A) all subjects (n=170), *= p b 0.05 and **= p b
0.001 for difference between indicated group and control group; B) in the mutation
carriers (G+/LVH+ and LVH−, n = 140) stratiﬁed by age group. LVH = LV
hypertrophy by any used criteria: Sokolow-Lyon criteria, Cornell voltage-duration
product or Romhilt-Estes point score, QR = Q waves and repolarization abnormalities.compared to the control and G+/LVH− group. The subjects in G+/
LVH+ group were also older compared to the G+/LVH− group (48
± 14 vs 33 ± 15 years, p b 0.001). The majority of the HCM patients
were asymptomatic (78%). By deﬁnition, the G+/LVH+ group had
signiﬁcantly greater maximal wall thickness. The groups were balanced
regarding left ventricular dimensions and ejection fraction. Left ventric-
ular outﬂow tract obstruction was present at rest in 5 (5%) of HCM
patients (a gradient of N30mmHg). Themajority of G+/LVH+patients
had asymmetric septal hypertrophy (90%). Eight (8%) of the HCM
patients had MWT in the lateral wall and one patient had posterior
and another patient concentric hypertrophy. Two patients had MWT
in the apical segments but also exhibited signiﬁcant thickening of the
whole septal wall and did not represent true apical hypertrophy. No
differences in echocardiographic measurements were found between
the G+/LVH− and control groups.
ECG
The ECG pathology ﬁndings are summarized in Table 2. There were
14 subjects (47%) in the control group with no ECG pathology in
comparison to 6 (14%) and 3 (3%) in the G+/LVH− and G+/LVH+
groups, respectively (p b 0.001). Thus the ﬁnding of a completely nor-
mal ECG was uncommon in all mutation carriers including G+/LVH−
subjects. The median number of ECG pathology was 1 (range 0–6) in
the G+/LVH− and 5 (0–9) in the G+/LVH+ groups. A normal ECG
with no identiﬁed pathology had a sensitivity of 47% and a speciﬁcity
of 96% to discern control subjects from HCM mutation carriers. Q
waves and repolarization abnormalities (QR) were common ﬁndings
in the G+/LVH+ group. The presence of Q waves, ST depression and
T-wave inversion was marked also in the G+/LVH− group (33%). ST
depressions were associated with inverted T waves in 34/50 (68%) of
the G+/LVH+ patients. Conventional ECG parameters of hypertrophy
(Sokolow-Lyon and Cornell criteria) identiﬁed true LVH quite modestly
in the G+/LVH+ group. The presence of P-terminal force, was aTable 2
ECG characteristics of the study groups.
Control G+/LVH− G+/LVH+ p-Value
(n= 30) (n= 42) (n= 98)
ECG pathology 1 (0–4) 1 (0–6) 5 (0–9)⁎,† b0.001
No ECG pathology 47% (14) 14% (6)⁎ 3% (3)⁎,† b0.001
Major criteria 3% (1) 36% (15)⁎ 90% (88)⁎,† b0.001
Q waves and repolarization 0 33% (14)⁎ 82% (80)⁎,† b0.001
Q waves 0 21% (9)⁎ 38% (37)⁎ b0.001
Q V2–V6 7% (3) 15% (15) 0.031
Q II, III, aVF 10% (4) 16% (16) 0.035
Q I, aVL 2% (1) 16% (16) 0.004
ST depression 0 7% (3) 51% (50)⁎,† b0.001
T-wave inversion 0 2% (1) 44% (43)⁎,† b0.001
Prolonged QTc 0 7% (3) 18% (18)⁎ 0.006
Absent Q V5–6 7% (2) 12% (5) 15% (15) 0.539
Giant T-waves 10% (3) 17% (7) 6% (6) 0.179
Novel ECG criteria
RV1bRV2NRV3 3% (1) 33% (14)⁎ 26% (25)⁎ 0.005
Septal remodeling 3% (1) 45% (19)⁎ 49% (48)⁎ b0.001
Maximal R-wave not in V4–6 7% (2) 19% (8) 23% (23) 0.122
Hypertrophy 10% (3) 17% (7) 66% (65)⁎,† b0.001
Sokolow-Lyon criteria 10% (3) 2% (1) 15% (15) 0.079
Cornell criteria 0 7% (3) 40% (39)⁎,† b0.001
Romhilt-Estes score ≥ 4 3% (1) 14% (6) 55% (54)⁎,† b0.001
Other ECG features
P-terminal force 3% (1) 17% (7) 45% (44)⁎,† b0.001
QRS N100 ms 0 5% (2) 22% (22)⁎,† b0.001
Fragmented QRS 27% (8) 21% (9) 46% (45)† 0.011
Prolonged PQ 0 2% (1) 11% (11) 0.032
Axis deviation 3% (1) 19% (8) 1% (1)⁎ 0.002
ECG pathology presented as median and range in parentheses. All other variables
presented as percentage and number of patients in parentheses.
⁎ p b 0.05 for difference between indicated group and control group.
† p b 0.05 for difference between G+/LVH+ and G+/LVH− groups.
Table 3
Correlation of variables to the extent of ECG pathology.
Variable ECG pathology
ρ p
ECHO E/E′ 0.58 b0.001
ECHO global systolic longitudinal strain 0.56 b0.001
ECHO mechanical dispersion 0.58 b0.001
CMRI LGE extent 0.62 b0.001
CMRI LV mass index 0.58 b0.001
CMRI maximal wall thickness 0.76 b0.001
NT-proBNP 0.62 b0.001
Spearman rank correlation of echocardiographic (ECHO) and cardiac magnetic resonance
imaging (CMRI) variables and NT-proBNP to the extent of ECG pathology in subjects with
the HCM-causing variant (0–15). LGE = late gadolinium enhancement.
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subjects. No signiﬁcant differences between the groups were observed
in the following parameters (not shown in the table): RI + SIII
N25 mm, RI + SIII-RIII-SI N17mm, S N R V4, PRWP, reverse R-wave pro-
gression in leads V1–V3.
The novel ECG criteria of RV1bRV2NRV3 (Fig. 1) and septal remodel-
ing were signiﬁcantly more common in mutation carriers without LVH
than in control subjects (33% vs 3%, p = 0.006 and 45% vs 3%, p b
0.001, respectively) and in G+/LVH+ subjects compared with control
subjects (26% vs 3%, p = 0.015 and 49% vs 3%, p b 0.001, respectively).
In univariate binary logistic regression, with age and sex as covariates,
both RV1bRV2NRV3 and septal remodeling retained their statistical sig-
niﬁcance (OR= 13.3, p = 0.018 for RV1bRV2NRV3 and OR= 21.8, p =
0.004 for septal remodeling).
Fig. 2B illustrates the different ECG ﬁndings stratiﬁed by age groups
in the mutation carriers with and without LVH (G+, n = 140).
RV1bRV2NRV3 and septal remodeling were more prevalent in younger
subjects and, in contrast, the ECG ﬁndings of hypertrophy and QR
were more pronounced in the older age groups.Imaging substudy
The baseline characteristics of the imaging substudy groups are pre-
sented in Supplementary Tables 1 and 2. CMRI derived ejection fraction
and LV end diastolic volume were normal in all study groups. Typical
imaging ﬁndings in subjects with mild and moderate HCM were in-
creased septal andmaximal wall thickness, increased CMRI LVmass, re-
duced diastolic function and global longitudinal strain (GLS), and
presence of LGE that increased with advanced disease. The prevalence
of RV1bRV2NRV3, septal remodeling and other key pathologic ECG fea-
tures according to HCM phenotype are illustrated in Fig. 3.
RV1bRV2NRV3wasmore prevalent in G+/LVH− andmutation carriers
with mild LVH than in patients with moderate or severe HCM. Other
ECG ﬁndings were more prevalent in the moderate HCM group com-
pared to the mild HCM and G+/LVH− groups. No signiﬁcant correla-
tions of the novel ECG parameters RV1bRV2NRV3 and septal
remodeling to imaging ﬁndings related to the septum or distribution
of wall thickness in segmental strain, LGE or MWT values were found.
The correlations of the extent of ECG pathology (0–15) to imaging and
laboratory variables in gene mutation carriers with and without LVH
are presented in Table 3, showing strong association with E/Em, GLS,Fig. 3.Distribution of ECG variables according toHCMgeno- and phenotype in the imaging
substudy subjects (n = 65): Control, G+/LVH−, G+/Mild HCM, G+/Moderate HCM.
Moderate HCM determined as MWT and/or GLS and/or LGE ≥75th percentile and mild
HCM as not fulﬁlling these criteria. RV1bRV2NRV3 is more prevalent in LVH− and mild
HCM subjects whereas presence of septal remodeling increases with changes related to
HCM. LVH = LV hypertrophy by any used criteria: Sokolow-Lyon criteria, Cornell
voltage-duration product or Romhilt-Estes point score, PTF = P-terminal force
≥0.04 mm·s, QR= Q waves and repolarization abnormalities.mechanical dispersion, LGE, LVmass index,MWT, and levels of circulat-
ing NT-proBNP.
The ECGﬁnding of QR had good sensitivity (95%) and relatively good
speciﬁcity (84%) for the presence of LGE (95% of patients with LGE had
QR compared to 16% of patients without LGE, p b 0.001 for Fisher's exact
test). There were no signiﬁcant correlations between the localization of
LGE and localized ECG-ﬁndings such as Q waves or T-wave inversion in
the anterior or inferior leads.
The ability of ECG ﬁndings to differentiate between study groups
Table 4 shows the diagnostic value of ECG parameters and their
combination for differentiating mutation carriers with and without
LVH from the control subjects. The major ECG criteria [22] performed
well in differentiating G+/LVH+ patients from control subjects, with
a sensitivity of 90% and speciﬁcity of 97%. The novel parameters of
RV1bRV2NRV3 and septal remodeling did not improve the diagnostic
sensitivity of the previously proposed criteria in differentiating G+/
LVH+ patients from control subjects. Conventional variables such as
themajor criteria or QR hadmodest sensitivity to differentiate between
G+/LVH− and control subjects. In contrast, RV1bRV2NRV3 and septal
remodeling bothhad incremental value in the identiﬁcation ofmutation
carriers without LVH.When used in conjunction with QR the sensitivity
was 52% and 64%, respectively, with a speciﬁcity of 97%.
Discussion
The main ﬁndings of this study are: 1) a normal ECG is rare (3%) in
HCM patients with TPM1-Asp175Asn orMYBPC3-Gln1061X variants in
a comprehensive ECG analysis; 2) a normal ECG is also uncommon
(14%) in G+/LVH− subjects; 3) the extent of ECG pathology correlates
with severity of the HCM phenotype; 4) novel ECG parameters
RV1bRV2NRV3 and septal remodeling were very speciﬁc to carriers ofTable 4
Effectiveness of ECG variables to separate G+/LVH+and G+/LVH− groups from the con-
trol group.
Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%)
G+/LVH+ (n = 98)
Major criteria (≥1) 90% 97% 99% 74%
QR 82% 100% 100% 63%
RV1bRV2NRV3 26% 97% 96% 28%
Septal remodeling 49% 97% 98% 37%
G+/LVH− (n = 42)
Major criteria (≥1) 36% 97% 94% 52%
QR 33% 100% 100% 52%
RV1bRV2NRV3 33% 97% 93% 51%
RV1bRV2NRV3 and/or QR 52% 97% 96% 59%
Septal remodeling 45% 97% 95% 56%
Septal remodeling and/or QR 64% 97% 96% 66%
NPV= negative predictive value, PPV= positive predictive value, QR= Qwaves and re-
polarization abnormalities.
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ters with the combination of Q waves and repolarization abnormalities
exhibited good sensitivity and excellent speciﬁcity to differentiate the G
+/LVH− group from the control group.
Study ﬁndings in the context of current literature
The novel ECG criteria RV1bRV2NRV3 and septal remodeling pro-
posed in this study have good speciﬁcity to differentiate between car-
riers of pathogenic variants for HCM and the control group. Previous
reports on the ECG ﬁndings of G+/LVH− subjects have been varied
and longitudinal follow-up data is scarce [7,8,10]. Some smaller scale
studies have reported Q waves and repolarization abnormalities [9],
while in others there have been very limited ECG ﬁndings [7]. The larg-
est published G+/LVH− cohort to date of 76 subjects with a number of
different variants, reported Qwaves and repolarization abnormalities in
25% of subjects, a ﬁnding that was a speciﬁc (98%) marker for young
LVH− variant carriers (42% of subjects in the study were b18 years
old) [8]. In the current study Q waves were present in 21% of G+/LVH
− subjects compared with none in the control group.
Previously the low sensitivity and mostly limited speciﬁcity of ECG
variables to differentiate G+/LVH− subjects from healthy control indi-
viduals has made their use in clinical practice challenging. In this study
the combination of RV1bRV2NRV3 or septal remodeling with Q waves
and repolarization abnormalities resulted in a signiﬁcant improvement
of the sensitivity of the ECG analysis to over 50%with a concurrent spec-
iﬁcity of 97%. Application of the RV1bRV2NRV3+ QR criteria especially
is relatively easy in clinical daily practice and could be used in the
screening of HCM families.
According to our study, ECG criteria for HCM identiﬁed pathogenic
variant carriers with LVH with high sensitivity, speciﬁcity and positive
likelihood ratio and compared well to a previous study with a similar
age distribution [10]. The extent of ECG pathology and degree of hyper-
trophy and dysfunction of the left ventricle correlatedwith the extent of
ECG pathology, which corroborates a previous ﬁnding [25]. We also
found that GLS, a sensitive marker of LV dysfunction, and NT-proBNP,
an established marker of disease severity and prognosis in HCM, both
correlate strongly to the extent of ECG pathology. These ﬁndings are of
importance in the clinical follow-up ofHCMpatients, as the ECG is an in-
expensive and reproducible test.
In our study, the Sokolow-Lyon criteria performed suboptimally in
identifying LVH, with only 15% fulﬁlling the criteria in the G+/LVH+
group and 10% in the control group. The Cornell criteria were positive
in 40% and the Romhilt-Estes score in 55% of the hypertrophic patients
- results that were in line with previous studies [26]. None of the LVH
criteria differed signiﬁcantly in prevalence between the G+/LVH−
and control groups.
Possible pathophysiological mechanisms
The novel ECG parameter proposed in this study, the RV1bRV2NRV3
sign, represents a disorderly distribution of themaximal R-wave ampli-
tudes in leads V1–V3. Normally the R-wave amplitude increases from
V1 to V3. Although not speciﬁcally reported, previous publications
have shown subjects with the RV1bRV2NRV3 pattern - both HCM pa-
tients with LVH in the age range of 10 to 69 years [27,28] and in patho-
genic variant carriers without echocardiographic ventricular
hypertrophy [4,6].
The RV1bRV2NRV3 ﬁnding is more prevalent in young subjects
(Fig. 2B) and in those with mild HCM (Fig. 3). It is possible that this re-
ﬂects an early stage of the developing disease as a segmental structural
change of the interventricular septum and is later substituted with
other more pronounced ECG changes due to signiﬁcant hypertrophy
and ﬁbrosis. However, even with comprehensive modern imaging
echocardiographic and CMRI methods, we could not identify signiﬁcantcorrelation between the RV1bRV2NRV3 sign and characteristics of the
interventricular septum of G+/LVH− subjects.
In our previous report, the presence of septal remodeling identiﬁed
DCM patients either with the lamin A/C variant (82% prevalence) or
no identiﬁed gene substrate (21%) compared to control subjects (0%)
[23]. Thus it is not a speciﬁc ﬁnding for HCM and instead might reﬂect
general LV remodeling of patients with cardiomyopathies of different
etiologies. No clear correlation of the location of LGE to Q waves was
found in this study reﬂecting the results of previous larger scale CMRI
reports [12,25]. On the other hand, the presence of Qwaves and repolar-
ization abnormalities was signiﬁcantly more prevalent in patients with
LGE.Limitations of the study
We studied carriers of two different pathogenic variants of HCM:
MYBPC3-Gln1061X and TPM1-Asp175Asn. Both are prevalent in the
Finnish HCM population and as such are probably similar to other path-
ogenic MYBPC3 and TPM1 variants causing HCM. Therefore, we would
presume that the results are generalizable to the spectrum of carriers
of pathogenic variants in these two genes. The results of this study
have to interpret with caution when discussing the diagnostics and
screening of families without a known pathogenic variant. The imaging
subset sample size was limited and included only subjects with the
MYBPC-Gln1061X variant. Thus, the results of the imaging study have
to be interpreted with caution.Conclusions
Our study shows that G+/LVH+patients can be identiﬁedwith high
sensitivity, speciﬁcity and predictive values. Conventional ECGwas also
valuable in the identiﬁcation of G+/LVH− subjects from control sub-
jects using the novel ECG parameters of RV1bRV2NRV3 and septal re-
modeling in combination with Q waves and repolarization
abnormalities. This ﬁnding needs to be further evaluated in larger pa-
tient cohorts, but holds promise as a clinically feasible tool to identify
subjects with preclinical changes of HCM and aid in the screening and
follow-up of relatives of HCM patients.
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